Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 61.7 EUR -0.08% Market Closed
Market Cap: 3.1B EUR
Have any thoughts about
Laboratorios Farmaceuticos ROVI SA?
Write Note

Laboratorios Farmaceuticos ROVI SA
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Laboratorios Farmaceuticos ROVI SA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Pre-Tax Income
€280.1m
CAGR 3-Years
13%
CAGR 5-Years
40%
CAGR 10-Years
27%
Almirall SA
MAD:ALM
Pre-Tax Income
-€1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
29%
F
Faes Farma SA
MAD:FAE
Pre-Tax Income
€109.7m
CAGR 3-Years
6%
CAGR 5-Years
0%
CAGR 10-Years
15%
Laboratorio Reig Jofre SA
MAD:RJF
Pre-Tax Income
€13.3m
CAGR 3-Years
29%
CAGR 5-Years
3%
CAGR 10-Years
24%
No Stocks Found

Laboratorios Farmaceuticos ROVI SA
Glance View

Market Cap
3.2B EUR
Industry
Pharmaceuticals
Economic Moat
Narrow

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

ROVI Intrinsic Value
87.01 EUR
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Laboratorios Farmaceuticos ROVI SA's Pre-Tax Income?
Pre-Tax Income
280.1m EUR

Based on the financial report for Sep 30, 2024, Laboratorios Farmaceuticos ROVI SA's Pre-Tax Income amounts to 280.1m EUR.

What is Laboratorios Farmaceuticos ROVI SA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
27%

Over the last year, the Pre-Tax Income growth was -24%. The average annual Pre-Tax Income growth rates for Laboratorios Farmaceuticos ROVI SA have been 13% over the past three years , 40% over the past five years , and 27% over the past ten years .

Back to Top